- Home
- CII vs PRCT Comparison
CII vs PRCT Comparison
Compare CII & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CII | PRCT |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CII | PRCT |
|---|---|---|
| Price | $25.74 | $20.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $35.44 |
| AVG Volume (30 Days) | 61.2K | ★ 1.9M |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | ★ 6.17% | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | N/A | $31.34 |
| Revenue Next Year | N/A | $24.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $20.43 | $19.35 |
| 52 Week High | $26.17 | $62.17 |
Technical Indicators
Market Signals| Indicator | CII | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 60.28 | 40.52 |
| Support Level | $23.04 | $19.64 |
| Resistance Level | $26.14 | $29.27 |
| Average True Range (ATR) | 0.46 | 1.47 |
| MACD | 0.04 | -0.09 |
| Stochastic Oscillator | 78.53 | 27.71 |
Price Performance
Historical ComparisonAbout CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. It may invest directly in such securities or synthetically through the use of derivatives. It also seeks to achieve its investment objective by employing a writing (selling) call and put options.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.